Neurocrine Biosciences NBIX Asset turnover
Asset turnover at other companies
Other financials
Where this comes from
Calculated from Neurocrine Biosciences’s reported figures.
Based on trailing twelve months.
The official record: Neurocrine Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Neurocrine Biosciences's asset turnover.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Neurocrine Biosciences's asset turnover?
- Neurocrine Biosciences (NBIX) reported asset turnover of 0.7× in Q1 2026.
- How has Neurocrine Biosciences's asset turnover changed year-over-year?
- Neurocrine Biosciences's asset turnover increased by 7.1% year-over-year, from 0.7× to 0.7×.
- What is the long-term trend for Neurocrine Biosciences's asset turnover?
- Over 4 years (2021 to 2025), Neurocrine Biosciences's asset turnover has grown at a 2.9% compound annual growth rate (CAGR), from 2.4× to 2.7×.
- What does asset turnover mean?
- How many sales dollars the company generates from each dollar of assets.
- How do you interpret asset turnover?
- Higher turnover means a more sales-efficient asset base. Low-margin businesses (retail, distribution) compete on high turnover; high-margin ones (software, luxury) on margin.
- How does asset turnover compare across companies?
- Compare within an industry — turnover differences across sectors reflect business models, not performance.